Registration is open for the 46th annual San Antonio Breast Cancer Symposium, Dec. 5–9, at the Henry B. Gonzalez Convention Center. Experts will lead symposium discussions on clinical, translational and basic research. Attendees will receive information on experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. Click here to register.
Researchers from the Mays Cancer Center at UT Health San Antonio presented results of multiple lines of study during the San Antonio Breast Cancer Symposium, operated in conjunction with the American Association of Cancer Research.
Lindsay Fry is a breast cancer survivor who was first diagnosed in 2019. Her treatment regimen of surgery, radiation and chemotherapy began in fall 2019. Shortly after completing her treatment, Fry became the first participant in a new clinical trial at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) that aims to help breast cancer survivors regain their energy and remain cancer free.
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumabwhen given in combination with trastuzumab emtansine compared with placebo andtrastuzumab emtansine for patients with residual invasive HER2-positive breast cancerfollowing neoadjuvant taxane-based and HER2-targeted therapy including trastuzumab, whoare at high risk of disease recurrence. The primary endpoint for this study is invasivedisease-free survival (IDFS).
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
Mays Cancer Center at UT Health San Antonio, in partnership with the American Association for Cancer Research (AACR), is hosting the 46th annual San Antonio Breast Cancer Symposium (SABCS) at the Henry B. Gonzalez Convention Center on Dec. 5-9. This scientific and education symposium, initiated and owned by Mays Cancer Center, is the world’s largest […]
Natalie Poullard, MA, MS, CGC, a certified genetic counselor at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, provides a brief understanding of genetic testing benefits, the types of tests available and what you can expect during an appointment. Watch here
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.
Close
